Clinical Trial Update: A Study of PF-06873600 in People With Cancer [Phase 1, Phase 2]

View source ↗

Summary

Pfizer's PF-06873600 in Phase 1/2 for several cancers was terminated, with results posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PF-06873600

Snippet

Sponsor: Pfizer | Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-31